Section Review: Biologicals & Immunologicals: Monoclonal antibodies in organ transplantation

References

• KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predermed specificity. Na-ture (1975) 256:495-497. How it all began.
   Google Scholar
• EMERY SC, ADAIR JR: Humanised monoclonal antibodies for therapeutic applications. Exp. Opin. Invest. Drugs(1994) 3:241-251. Excellent review about humanised antibodies.
   Google Scholar
• KREIS H, LEGENDRE C, CHATENOUD L: OKT3 in organ transplantation. Transplant Rev. (1991) 5:181–199.
   Google Scholar
• NORMAN DJ, LEONE MR: The role of OKT3 in clinical transplantation. Pediatr. Nephrol. (1991) 5:130–136.
   PubMed Web of Science ®Google Scholar
• JANSSEN 0, WESSELBORG S, KABELITZ D: Inamunosup-pression by OKT3-induction of programmed cell death (apoptos is) as a possible mechanism of action. Trans-plantation (1992) 53:233–234.
   Google Scholar
• ALEGRE ML, PETERSON LJ, XU D, SATTAR HA, JEYARAJAFIDR, KOWALKOWSKI K, THISTLETHWAITE JR, ZIVIN RA, JOLLIFEE L, BLUESTONE JA: A non-activating human-ized' anti-CD3 monoclonal antibody retains irrununo-suppressive properties in vivo. Transplantation (1994) 57:1537–1543.
   PubMed Web of Science ®Google Scholar
• NASHAN B, WONIGEIT K, SCHWINZER R, SCHLITT HJ,KURRLE R, PICHLMAYR R: Fine specificity of a panel of antibodies against the TCR/CD3 complex. Transplant Proc. (1987) 19:4270–4272.
   PubMed Web of Science ®Google Scholar
• NASHAN B, SCHWINZER R, WONIGEIT K, PICHLMAYR R:Reaction of patient antlsera to OKT3 with a panel of CD3 monoclonal antibodies. Transplant Proc. (1989) 21:985–986.
   PubMed Web of Science ®Google Scholar
• PFEFFER PF, OHLMAN S, JAKOBSEN A, FAL'CHA_LD P, LEIVESTAD T, TYDEN G, FLATMARK A: A Scandinavian two-center study of BMA 031 in steroid-resistant rejec-tion of renal grafts. Transplantation (1993) 56:304–307.
   PubMed Web of Science ®Google Scholar
• WAID TH, LUCAS BA, THOMPSON JS: Treatment of acute cellular rejection with T10119.1A-31 or OKT3 in renal allograft recipients. Transplantation (1992) 53:80–86.
   Google Scholar
• VANDEKERCKHOVE BAE, DATEMA G, KONING F, GOULMY E, PERSIJN GG, VAN ROOD JJ, CLAAS FHJ, DE VRIES JE: Analysis of the donor-specific cytotoxic phocyte repertoire in a patient with a long term surviv-ing allograft: Frequency, specificity, and phenotype of donor-reactive T-cell receptor (TCR)-aii+ and TCR-y8+ clones. J. Immunol. (1990) 144:1288-1294. Fundamental paper about donor-reactive T-cells in a transplant patient.
   Google Scholar
• AKBAR AN, AMLOT PL, HAWKINS C, NEWSHOLME W, DELANEY S, BORTHWICK N, JANOSSY G: The effect of chimeric mouse-human CD7 antibody on human T, natural killer, and lymphokine activated killer cell activity in vitro. Transplantation (1991) 52:325–330.
   PubMed Web of Science ®Google Scholar
• LAZAROVITS Al, ROCHON J, BANKS L, HOLLOMBY DJ,MUIRHEAD N, JEVNIKAR AM, WHITE MJ, AMLOT PL, BEAUREGARD ZOLLINGER L, STILLER CR: Human mouse chimeric CD7 monoclonal antibody (SDZCHH380) for the prophylaxis of kidney transplant rejection. J. Immu-no/. (1993) 150:5163–5174.
   PubMed Web of Science ®Google Scholar
• AMLOT PL: Unpublished data.
   Google Scholar
• ISOBE M, YAGITA H, OKUMURA K, LHARA A: Specific acceptance of cardiac allograft after treatment withantibodies to ICAM-1 and LFA-1. Science (1992) 255:1125-1127. Key paper about transplant tolerance induction with antibodies against adhesion molecules.
   Google Scholar
• OMURA T, ISHIKURA H, NAKAJIMA Y, TAKAHASHI C, KIMURA J, UCHINO J, YOSHIKI T: Accelerated rejection of allografted rat liver perfused with anti-ICAM-1 mono- clonal antibody. Immunobiol. (1992) 186:241-245. Critical paper about pre-transplant organ perfusion with an ICAM1 antibody.
   Google Scholar
• ROTHLEIN R: Unpublished data.
   Google Scholar
• PEDLEY RB, BODEN JA, BODEN R, BEGENT RH, TURNERA, HAINES AM, KING DJ: The potential for enhanced tumour localisation by poly(ethylene glycol) modifica-tion of anti-CEA antibody. Br. J. Cancer (1994) 70:1126–1130.
   PubMed Web of Science ®Google Scholar
• GASSEL J, IIMMERMANN W: Unpublished data.
   Google Scholar
• ROMER K, HERWARTZ C, STEINMANN J: Unpublished data.
   Google Scholar
• SINGER II, KAWKA DW, DEMARTINO JA, DAUGHERTY BL, ELLISTON KO, ALVES K, BUSH BL, CAMERON PM, CUCA GC, DAVIES P, ET AL : Optimal humanization of 1B4, an anti-CD18 murine monoclonal antibody, is achieved by correct choice of human V-region framework se-quences. J. Immunol. (1993) 150:2844-2857. Well written technical paper.
   Google Scholar
• AVERSANO T, ZHOU W, NEDELMAN M, NAKADA M, WEIS- MAN H: A chimeric IgG4 monoclonal antibody directed against CD18 reduces infarct size in a primate model of myocardial ischemia and reperfusion. J. Am. Coll. Cardiol. (1995) 25:781–788.
   PubMed Web of Science ®Google Scholar
• HSIAO KC, BAJORATH J, HARRIS LJ: Humanization of 60.3, an anti-CD18 antibody; importance of the L2 loop. Protein Eng. (1994) 7:815–822.
   Google Scholar
• FURIE MB, TANCINCO MC, SMITH CW: Monoclonal anti-bodies to leukocyte integrins CD11a/CD18 and CD11b/CD18 or intercellular adhesion molecule-1 in-hibit chetnoattractant-stimulated neutrophil transen-dothelial migration in vitro. Blood (1991) 78:2089–2097.
   PubMed Web of Science ®Google Scholar
• SHREENIWAS R, OGAWA S, COZZOLINO F, TORCIA G, BRAUNSTEIN N, BUTURA C, BRETT J, LIEBERMAN HB, FUZEE MB, JOSEPH SILVERSTEIN J, ET AL.: Macrovascular and microvascular endothelium during long-term hy-poxia: alterations in cell growth, monolayer permeabil-ity, and cell surface coagulant properties. J. Cell Physiol. (1991) 146:8–17.
   Google Scholar
• LO SK, VAN SEVENTER GA, LEVLN SM, WRIGHT SD: Two leukocyte receptors (CD11a/CD18 and CD11b/CD18) mediate transient adhesion to endothelium by binding to different ligands. J. Immunol. (1989) 143:3325–3329.
   PubMed Web of Science ®Google Scholar
• LO SK, DETMERS PA, LEVIN SM, WRIGHT SD: Transient adhesion of neutrophils to endothelium. / Exp. Med. (1989) 169:1779–1793.
   PubMed Web of Science ®Google Scholar
• HARLAN JM, KILLEN PD, SENEGAL FM, SCHWARTZ BR, YEEEK, TAYLOR RE, BEATTY PG, PRICE TH, OCHS HD: The role of neutrophil membrane glycoprotein GP-150 in neutrophil adherence to endothelium in vitro. Blood (1985) 66:167–178.
   PubMed Web of Science ®Google Scholar
• COLAMONICI OR, NECKERS LM, ROSOLEN A: Putative gamma-subunit of the 11–2 receptor is detected in low, intermediate and high affinity IL-2 receptor-bearing cells. J. Immunol (1990) 145:155-160. First paper about the IL-2 receptor 7 chain.
   Google Scholar
• HERVE P, WIJDENES J, BERGERAT JP, MILPIED N, GAUD C, BORDIGONI P: Treatment of acute graft-versus-host disease with monoclonal antibody to 11.-2 receptor. Lancet (1988) 11:1072–1073.
   Google Scholar
• REINSMOEN NL, BOLMAN RM, SAVIK K, BULIERS K, HERTZ M: Differentiation of class 1-and class 2-directed donor-specific alloreactivity in bronchoalveolar lavage lymphocytes from lung transplant recipients. Trans-plantation (1992) 53:181–189.
   Google Scholar
• HERWARTZ C, STEINMANN J. BETHKE U, ENGEMANN R, GASSEL J, HOFFMANN S, LEIMENSTOLL G, TIMMERMANN W, MULLER-RUCI 'HOLTZ W: Rejection prophylaxis with interleukin-2 receptor antibody BT563: mechanism on human cells. Transplant Int. (1992) 5\(Suppl. 1):684–687.
   Google Scholar
• TAZZARI PL, BOLOGNESI A, DE TOTERO D, PILERI S, CONTE R. WIJDENES J, HERVE P. SORIA M, STIRPE F, GOBBI M: B-B10 (anti-CD25)-saporin inununotoxin - a possible tool in graft-versus-host disease treatment Transplantation (1992) 54:351–356.
   Google Scholar
• 'BEREA F, TSCHELIESSNIGG RI-I, FREIGASSNER M, AUER T,KLEINERT R, WASLER A, PETUTSCHNIGG B, MULLER H: Clinical experience with a monoclonal interleuldn-2 receptor antibody (ir 563) for rejection therapy after orthotopk heart transplantation. Transplant Proc. (1994) 26:3237–3239,
   PubMed Web of Science ®Google Scholar
• NEUHAUS P, BECHSTEIN WO, BLUMHARDT G, WIENS M,LEMMENS P, LANGREHR JM, LOHMANN R, STEFFEN R, SCHLAG H, SLAMA KJ et al.: Comparison of quadruple imtnunosuppression after liver transplantation with ATG or IL-2 receptor antibody. Transplantation (1993) 55:1320–1327.
   Google Scholar
• SOULILLOU JP, LE MAUFF B, OLIVE D, DELAAGE M, PEYRONNET P, HOURMANT M, MAWAS C, HIRN M, JAC-QUES Y: Prevention of rejection of kidney transplants by monoclonal antibody directed against interleukin 2. Lancet (1987) H:1339–1342.
   Google Scholar
• CHABANNES D, MAUFF BL, HALLET MM, JACQUES Y, SOULILLOU JP: Effect of cyclosporin on interleukin 2 receptor expression in a human alloreactive T-cell done. Transplantation (1988) 46:97–100.
   Google Scholar
• CANTAROVICH D, LE MAUFF B, HOURMANT M, GIRAL M,DENIS M, HIRN M, JACQUES Y, SOULILLOU JP: Anti-Inter-leuldn 2 receptor monoclonal antibody in the treat-ment of ongoing acute rejection episodes of human kidney graft - a pilot study. Transplantation (1989) 47:454–457.
   PubMed Web of Science ®Google Scholar
• CANTAROVICH D, LE MAUFF B, HOURMANT M, GIRAL M,DENIS M, JACQUES Y, SOULILLOU JP: Anti-IL-2 receptor monoclonal antibody (3383.1) in prophylaxis of early kidney rejection in humans: a randomized trial versus rabbit antithymocyte globulin. Transplant Proc. (1989) 21:1769–1771.
   Google Scholar
• CANTAROVICH D, LE MAUFF B, HOURMANT M, GIRAL M,DENIS M, HIRN M, JACQUES Y, SOULILLOU JP: Treatment of acute kidney rejection episodes with monoclonal antibody directed against IL-2 receptor: a pilot study. Transplant Proc. (1989) 21:1785–1786.
   PubMed Web of Science ®Google Scholar
• HALLET M-M, PEYAT M-A, MOISAN J-P, SOULILLOU JP,MOREAU J-F: Proliferation dependence and production of 11-2 in human alloreactive T-cell clones. Cell Immunol. (1989) 124:95–106.
   PubMed Web of Science ®Google Scholar
• SOULILLOU JP, JACQUES Y: Monoclonal anti-112-receptor In organ transplantation. Transplant Int. (1989) 2:46–52.
   PubMed Web of Science ®Google Scholar
• BAATARD R, DANTAL J, HOURMANT M, CANTAROVICH D, CESBORN A, BIGNON JD, SOULILLOU JP: Effect of the number of pregraft blood transfusions in kidney graft recipients treated with bioreagents and cyclosporin A. Transplant Int. (1991) 4:235–238.
   Google Scholar
• DANTALJ, SOULILLOU JP: Use of monoclonal antibodies in human transplantation. Curr. Opin. Immunol. (1991) 3:740–747.
   PubMed Web of Science ®Google Scholar
• SOULILLOU JP, LE MAUFF B, CANTAROVICH D, HOUR-MANT M, VIE H, JACQUES Y: Use of a monoclonal antibody directed against interleukin 2 receptor in recipients of kidney allografts. Transplant Proc. (1992) 20\(Suppl. 6):84–86.
   Google Scholar
• SOULILLOU JP: Bioreagents in allograft immunosup-pression. Adv. Nephrol. Necker Hosp. (1992) 21:373–386.
   PubMedGoogle Scholar
• CANTAROVICH D, LE MAUFF B, HOURMANT M, DANTAL J, BAATARD R, DENIS M, JACQUES Y, KARAM G, PAINEAU J, SOULILLOU JP: Prevention of acute rejection episodes with an anti-interleukin 2 receptor monoclonal anti-body. Transplantation (1994) 57:198–203.
   PubMed Web of Science ®Google Scholar
• SOULILLOU JP: Relevant targets for therapy with mono- clonal antibodies in allograft transplantation. Kidney Int. (1994) 46:540–553.
   PubMed Web of Science ®Google Scholar
• SOULILLOU JP, CANTAROVICH D, LE MAUFF B, GIRAL M, ROBILLARD N, HOURMANT M, HIRN M, JACQUES Y: Ran-domized controlled trial of a monoclonal antibody against the interleukin-2 receptor (3383.1)as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts [see comments]. New Engl. J. Med. (1990) 322:1175–1182 .
   Google Scholar
• HOURMANT M, LE MAUFF B, CANTAROVICH D, DANTAL J, BAATARD R, DENIS M, JACQUES Y, KARAM G, SOULIL-LOU JP: Prevention of acute rejection episodes with an anti-interleulcin 2 receptor monoclonal antibody. IL Results after a second kidney transplantation. Trans-plantation (1994) 57:204–207.
   Google Scholar
• UCHTYAMA T, BRODER S, WAI DMANN TA: A monoclonal antibody (anti-tar) reactive with activated and function-ally mature human T-cells. L Production of anti-tac monoclonal antibody and distribution of tac(+)cells. J. Immunol. (1981) 126:1393–1397.
   Google Scholar
• DEPPER JM, LEONARD WJ, ROBB RJ, WALDMANN TA, GREENE WC: Blockade of the interleukin-2-receptor by anti-tac antibody: inhibition of human lymphocyte activation. J. Immunol. (1983) 131:690–696.
   PubMed Web of Science ®Google Scholar
• CARPENTER CB, KIRKMAN RL, SHAPIRO ME, MILFORD EL, TILNEY NL, WALDMANN TA, ZIMMERMAN CE, RAMOS CL, STROM TB: Prophylactic use of monoclonal anti-I1-2 receptor antibody in cadaveric kidney transplantation. Am.J, Kidney Dis (1989) 14:54–57,
   PubMed Web of Science ®Google Scholar
• OH-ISHI T, GOLDMAN CK, MISITI J, WALDMANN TA: The Interaction of interleuldn 2 with its receptor in the generation of suppressor T-cells in antigen-specific and antigen-non-specific systems in vitro. Clin. Immunol. Immunopath. (1989) 52:447–459.
   PubMedGoogle Scholar
• RAMOS CL, MILFORD EL, KIRKMAN RL, TILNEY NL, STROM TB, SHAPIRO ME, WALDMANN TA, WOOD IG, ROLLINS MR, CARPENTER CB: Differential 11-2 receptor expres-sion in renal allograft recipients treated with an antiff-2 receptor antibody. Transplantation (1989) 48:415–420.
   PubMed Web of Science ®Google Scholar
• RAMOS EL, MILFORD EL, KIRKMAN RL, TILNEY NL, STROM TB, SHAPIRO ME, WALDMANN TA, WOOD IG, ROLLINS MR, CARPENTER CB: Differential IL-2 receptor expres-sion in renal allograft recipients treated with an anti- IL-2-receptor antibody.Transplantation (1989)48:415–420.
   PubMed Web of Science ®Google Scholar
• REED MH, SHAPIRO ME, STROM TB, MILFORD EL, CAR-PENTER CB, WEINBERG DS, RELMANN KA, LETVIN NL, WALDMANN TA, KIRKMAN RL: Prolongation of primate renal allograft survival by anti-Tac, an anti-human 11-2 receptor monoclonal antibody. Transplantation (1989) 47:55–59.
   PubMed Web of Science ®Google Scholar
• BROWN PSJ, PARENTEAU GL, DIRBAS FM, GARSIA RJ, GOLDMAN CK, BUKOWSKI MA, JUNGHANS RP, QUEEN C, HAKIMI J, BENJAMIN VVR, CLARK RE, WALDMANN TA. Anti-Tac-H, a humanized antibody to the interleukin 2 receptor, prolongs primate cardiac allograft survival. Proc. Natl. Acad. Sci. USA (1991) 88:2663–2667.
   PubMed Web of Science ®Google Scholar
• KIRKMAN RL, SHAPIRO ME, CARPENTER CB, MCKAY DB,MILFORD EL, RAMOS EL, TILNEY NL, WALDMANN TA, ZIMMERMANN CE, STROM TB: A randomized prospective trial of anti-Mc monoclonal antibody in human renal transplantation. Transplant Proc. (1991) 23:1066–1067.
   PubMed Web of Science ®Google Scholar
• WALDMANN TA: Monoclonal antibodies in diagnosis and therapy. Science (1991) 252:1657–1662.
   PubMed Web of Science ®Google Scholar
• GRANT AL ROESSLER E, JU G, TSUDO M, SUGAMURA K,WALDMANN TA: The interleukin 2 receptor (IL-2R): the IL-2R alpha subunit alters the function of the IL-2R beta subunit to enhance 11-2 binding and signaling by mechanisms that do not require binding of IL-2 to IL-2R alpha subunit. Proc. Natl. Acad. Sci. USA (1992) 89:2165–2169.
   PubMed Web of Science ®Google Scholar
• PARENTEAU GL, DIRBAS FM, GARMESTANI K, BRECHBIEL MW, BUKOWSKI MA, GOLDMAN CK, CLARK R, GANSOW OA, WALDMANN TA: Prolongation of graft survival in primate allograft transplantation by yttrium-90-labeled anti-Tac in conjunction with granulocyte colony-stimu-lating factor. Transplantation (1992) 54:963–968.
   PubMed Web of Science ®Google Scholar
• HAKIMI J, HA VC, UN P, CAMPBELL E, GATELY MK, TSUDO M, PAYNE PW, WALDMANN TA, GRANT Aj, TSIEN WH et al.: Humanized Mik beta 1, a humanized antibody to the 11-2 receptor beta-chain that acts synergistically with humanized anti-TAC. J. Immunol. (1993) 151:1075–1085.
   PubMed Web of Science ®Google Scholar
• WALDMANN TA: The 11-2/IL-2 receptor system: a target for rational immune intervention. Immunol. Today (1993) 14:264-270. Concise review of the IL-2R blocking concept.
   Google Scholar
• ANASETTI C, HANSEN JA, WALDMANN TA, APPELBAUM FR, DAVIS J, DEEG HJ, DONEY K, MARTIN PJ, NASH R, STORM R et al.: Treatment of acute graft-versus-host disease with humanized anti-Tac: an antibody that binds to the interleukin-2 receptor. Blood (1994) 84:1320–1327.
   PubMed Web of Science ®Google Scholar
• KAMMIALER ME: Unpublished data.
   Google Scholar
• HERWARTZ C et al. Unpublished data.
   Google Scholar
• JACQUES Y, AUDRAIN M, BOEFFARD F, SOULILLOU JP: Concerted action of monoclonal antibodies directed at the p55 and p75 chains of the human interleuldn-2 receptor. Transplant Proc. (1991) 23:1068–1069.
   PubMed Web of Science ®Google Scholar
• AUDRAIN M, BOEFFARD F, SOULILLOU JP, JACQUES Y: Synergistic action of monoclonal antibodies directed at p55 and p75 chains of the human 11-2-receptor. J. Immunol. (1991) 146:884–892.
   PubMed Web of Science ®Google Scholar
• STEINMANN J, HERWARTZ C, MULLER-RUCHHOLTZ W: Interleukin4 bypass of the immunosuppressive effect mediated by interleukin-2 receptor antibodies. Scand. J. Immunol. (1993) 37:217–225.
   PubMed Web of Science ®Google Scholar
• VIE H, GAUTHIER T, BREATHNACH R, BONNEVILLE M, GODARD A, DIETRICH J, KARAM G, GESNEL M-C, PEYRAT M, JAQUES Y, SOULILLOU JP: Human fusion proteins between interleukin2 and IgM heavy chain are cyto-toxic for cells expressing the interleukin2 receptor. Proc. Natl. Acad. Sci. USA (1992) 89:11337–11341.
   PubMed Web of Science ®Google Scholar
• TINUBU SA, HAKIMI J, KONDAS JA, BAILON P, FAMILLETTIPC, SPENCE C, CRII1ENDEN MD, PARENTEAU GL, DIRBAS FM, TSUDO M, Bacher JD, KASTEN-SPORTES C, MARTINUCCI JL, GOLDMAN CK, CLARK RE, WALDMANN TA: Humanized antibody directed to the 11-2 receptor beta-chain prolongs primate cardiac allograft survivaL J. Immunol. (1994) 153:4330–4338.
   Google Scholar
• BOGERS WMJM, LANG F, PARKER RE, LE MAUFF B, ANE-GON I, JACQUES Y, SOULILLOU JP: Rat interleukin-2 immunoglobulin µ fusion proteins are cytotoxic in vitro for cells expressing the IL-2 receptor and can abolish cell-mediated immunity in vivo. Transplantation (1994) 58:932–939.
   PubMed Web of Science ®Google Scholar
• NOGUCHI M, YI H, ROSENBLATT JIM, FILIPOVICH AH,ADELSTEIN S, MODI WS, MCBRIDE OW, LEONARD WJ: Interleukin-2 receptor gamma chain mutation results in X-linked severe combined Mununodeficiency in hu-mans. Cell (1993) 73:147–157.
   PubMed Web of Science ®Google Scholar
• DISANTO JP, DAUTRY-VARSAT A, CERTAIN S, FISCHER A,DE SAINT BASILE G: Interleukin-2 (11-2) receptor gamma-chain mutations in X-linked severe combined itrununodeficiency disease result in the loss of high-af-finity IL-2 receptor binding. Eur. J. Immunol. (1994) 24:475–479.
   PubMed Web of Science ®Google Scholar
• COBBOLD SP: Monoclonal antibody therapy for the induction of transplantation tolerance. Immunol. Lett. (1991) 29:117–121.
   PubMed Web of Science ®Google Scholar
• EMMRICH F, FLUGEL A, BURMESTER G: Einsatz von monoklonalen Antikiirpern bei rheumatischen Erk-rankungen. Die gelben Hefte (1993) 23:160–171.
   Google Scholar
• NORMAN DJ, BENNE I I WM, COBANOGLU A, HERSHBER- GER R, HOSENPUD JD, MEYER MM, MISITI J, OTT G, RATKOVEC R, SHIHAB F et al • Use of OKT4A (a murine monoclonal anti-CD4 antibody) in human organ trans-plantation: initial clinical experience. Transplant Proc (1993) 25:802–803.
   PubMedGoogle Scholar
• HENELL KR, CHEEVER JM, KIMBALL JA, LYE WC, MUNARMY, MISM J, VITOW C, NORMAN DJ: OKT4A (a murine IgG2a anti-CD4 monoclonal antibody) in human organ transplantation: pharraacokinetics and peripheral pbarmacodynamics. Transplant Proc. (1993) 25:800–801.
   PubMed Web of Science ®Google Scholar
• MITCHISON A: T-cell activation states: the next break- through in signaling? Immunologist (1993) 1/3:78-80. Very well formulated point of view on T-cell activation.
   Google Scholar
• WALDMANN H, COBBOLD SP: The use of monoclonal 0antibodies to achieve immunological tolerance. Immu-nol. Today (1993) 14:247-251. Excellent overview on tolerance induction by antibodies.
   Google Scholar
• SABLINSKI T, HANCOCK WW, TILNEY NL, KUPIEC-WEG-LINSKI JW: CD4 monoclonal antibodies in organ trans-plantation - a review of progress. Transplantation (1991) 52:579–589.
   PubMed Web of Science ®Google Scholar
• STOPPA AM, MARANINCHI D, BLAISE D, VIENS P, HIRN M, OLIVE D, REIFFERS J, MILPIED N, GASPARD MET, MAWAS C: Anti-LFA1 monoclonal antibody (25.3) for treatment of steroid-resistant grade M-IV acute graft-versus-host disease. Transplant Int. (1991) 4:3–7.
   Google Scholar
• BLAISE D, OLIVE D, H1RN M, VIENS P, LAFAGE M, ATTAL M, STOPPA AM, GABERT J, GASTAUT JA, CAMERLO J, MANNONI P, MAWAS C, MARANINCHI D: Prevention of acute GVHD byin vivo use of anti-interleukin-2 receptor monoclonal antibody (33B3.1): a feasibility trial in 15 patients. Bone Marrow Transplant (1991) 8:105–111.
   Google Scholar
• COSIMI AB, CONTI D, DELMONICO FL, PREFFER Fl, WEE S-L, ROTHLEIN R, FAANES R, COLVIN RB: /n vivo effects of monoclonal antibody to ICAM-1 (CD54) in nonhu-man primates with renal allografts. J. Immunol. (1993) 144:4604–4612.
   Google Scholar
• HAUG CE, COLVIN RB, DELMONICO FL, AUCHINCLOSS H, TOLKOFF-RUBIN N, PREFEER Fl, ROTHLEIN R, NORRIS 5, SCHARSCHMIDT L, COSIMI AB: A Phase I trial of immu-nosuppression with anti-ICAM-1 (CD54) mAb in renal allograft recipients. Transplantation (1993) 55:766–773.
   PubMed Web of Science ®Google Scholar
• ADAIR JR, BRIGHT SM: Progress with humanised antibodies - An update. Exp. Opin. Invest. Drugs (1995) 4:863-870. Review providing a lot of unpublished, insider information.
   Google Scholar